No Data
No Data
H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Ram Selvaraju maintains $Entera Bio(ENTX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 36.8% and a
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients With Hypoparathyroidism at ENDO 2024
JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced Phase 1
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, toda
Express News | HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Entera Bio to Present Phase 1 Data From First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it
Entera Bio Releases Crucial Financial Information Update
No Data
diamonds : Excuse me, can shares held still be valid after ENDPQ's restructuring?